Parameter | All SSc (n= 26) | Diffuse cutaneous SSc (n= 6) | Limited cutaneous SSc (n= 20) |
---|---|---|---|
Age (years) | 56 ± 13 (32 to 75) | 50 ± 9 (40 to 66) | 46 ± 14 (32 to 75) |
Sex (% female) | 77 | 67 | 80 |
Disease duration (years) | 7.9 ± 5.3 (1 to 19) | 7.7 ± 6.0 (3 to 19) | 8.0 ± 5.2 (1 to 18) |
Modified Rodnan skin score | 8.3 ± 6.1 (2 to 19) | 16.3 ± 3.3 (12 to 19) | 5.8 ± 4.3† (2 to 18) |
Organ and tissue involvement | |||
Pulmonary fibrosis | 11 (42) | 6 (100) | 5 (25)** |
Pulmonary hypertension | 5 (19) | 3 (50) | 2 (10) |
Cardiac involvement | 6 (23) | 1 (17) | 5 (25) |
Gastrointestinal involvement | 2 (8) | 1 (17) | 1 (5) |
Active digital ulcer | 7 (27) | 0 (0) | 7 (30) |
History of digital ulcer | 16 (62) | 4 (83) | 12 (55) |
Arteriosclerotic disease | 3 (12) | 0 (0) | 3 (15) |
ESR (mm/hour) | 19 ± 14 | 28 ± 20 | 16 ± 11 |
Antinuclear antibody positivity | 23 (89) | 5 (83) | 18 (90) |
Anti-centromere antibody | 11 (42) | 0 (0) | 11 (55)* |
Anti-Scl70 antibody | 9 (35) | 2 (33) | 7 (35) |
Medication | |||
Immunomodulatory druga | 10 (38) | 2 (33) | 8 (40) |
Steroids | 6 (23) | 1 (17) | 5 (25) |
Iloprost | 12 (46) | 3 (50) | 9 (45) |
Calcium-channel blockers | 9 (35) | 2 (33) | 7 (35) |
Betablockers | 1 (4) | 0 (0) | 1 (5) |
Bosentan | 7 (27) | 3 (50) | 4 (20) |
Sildenafil | 3 (12) | 0 (0) | 3 (15) |
Low-dose aspirin | 5 (19) | 0 (0) | 5 (25) |
RAMRIS | 6.5 ± 4.7 (0 to 14) | 5.4 ± 4.1 (1 to 12) | 7.0 ± 5.0 (0 to 14) |
Radiographs of the hands | 21 (81) | 4 (67) | 17 (85) |
Signs of arthritis | 2 (10) | 0 (0) | 2 (12) |
Acroosteolysis | 9 (43) | 2 (50) | 7 (41) |
Soft-tissue calcifications | 11 (52) | 1 (25) | 10 (59) |
FFbH (% functional capacity) | 68.7 ± 22.8 (33 to 100) | 58.2 ± 25.2 (39 to 100) | 71.9 ± 21.7 (33 to 100) |
Health Assessment Questionnaireb | 1.24 ± 0.64 (0.36 to 2.25) | 1.54 ± 0.7 (0.36 to 2.08) | 1.15 ± 0.61 (0.36 to 2.25) |